Change in the serologic markers of hepatitis B after allogenic hematopoietic stem-cell transplantation.
10.3350/kjhep.2009.15.2.131
- Author:
Seong Yong WOO
1
;
Se Hyun CHO
;
Se Min LEE
;
Myoung Beom KOH
;
Chee Ho NOH
;
Chang Wook KIM
;
Jong Young CHOI
;
Jin Mo YANG
;
Joon Yeol HAN
;
Young Sok LEE
Author Information
1. Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea. chowhang@catholic.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Hepatitis B virus;
Allogenic hematologic stem cell transplantation
- MeSH:
Adolescent;
Adult;
Aged;
Biological Markers/blood;
Female;
*Hematopoietic Stem Cell Transplantation;
Hepatitis B/diagnosis/*immunology;
Hepatitis B Antibodies/blood;
Hepatitis B Surface Antigens/blood;
Humans;
Male;
Middle Aged;
Retrospective Studies;
Tissue Donors;
Transplantation, Homologous;
Virus Activation
- From:The Korean Journal of Hepatology
2009;15(2):131-139
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: This study examined the effects of hepatitis B virus (HBV) infection state and immunologic capability in both the recipients and donors of allogenic hematopoietic stem-cell transplantation (allo-HSCT) on changes in HBV serologic markers in recipients. METHODS: A total of 537 patients underwent allo-HSCT for the treatment of leukemia, malignant lymphoma, and solid tumor. HBV serologic markers were examined in both recipients and donors prior to and following the transplantation. The mean follow-up period was 36.6 months (range 3-80 months). RESULTS: Of the 537 patients who underwent allo-HSCT, 45 recipients were positive for HBsAg prior to transplantation. Of these 45 patients, 21 were transplanted from anti-HBs-positive donors and the remaining 24 were transplanted from anti-HBs-negative donors. In the former cases, seroconversion was noted in 4 of the 21 patients (19%). In the latter cases, however, no seroconversion was noted following the transplantation. Thirty patients who were negative for both HBsAg and anti-HBs were transplanted from anti-HBs-positive donors, and 15 out of 30 patients (50%) acquired anti-HBs. Four hundred and seven patients who were positive for anti-HBs were transplanted from anti-HBs-positive or HbsAg-negative donors; 8 of these proved HBsAg-positive following the transplantation. There were no changes in HBV serological markers following transplantation in 41 patients who were transplanted from HbsAg-positive donors. CONCLUSIONS: Due to the adoptive immunity that was transferred from anti-HBs-positive donors, a seroconversion of HBsAg could occur in some HBsAg-positive recipients. HBsAg-positive donors had a lesser effect on the HBV serologic markers of recipients. However, a reactivation of HBV can occur following hematopoietic stem-cell transplantation in the cases of recipients or donors with a history of HBV, infection by an accompanying immune suppression. Therefore, prevention should be instigated.
